Study Group: Fuzeon Prescribers for HIV (US)
Council Members in this Study Group: 43
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Calvin Cohen
Research Director
COMMUNITY RESEARCH INITIATIVE OF NEW ENGLAND INC
Calvin Cohen, MS, MD, is Research Director for both Harvard Vanguard Medical Associates and CRI New England in Massachusetts, a nonprofit organization he co-founded in 1990 to focus on HIV clinical trials. He is also on the faculty of Harvard Medical...
- Steven Fine
Physician
UNIVERSITY OF ROCHESTER MEDICAL CENTERSteven Fine, MD, PhD, is an HIV and Infectious Disease specialist, an Assistant Professor in the Infectious Disease Unit at the University of Rochester Medical Center, and Staff Physician at Community Health Network. His clinical expertise is all aspects...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Simple potent and safe. This HIV combination will be hard to beat.
August 4, 2006
Analysis by: Steven Fine, Physician,New AIDS Pill Simplifies Treatment | www.therapeuticsdaily.com
A three drug "cocktail" for treating HIV all in one pill once a day.
The individual components used together but as individual pills have already proven to be among the most potent and safest regimens for patients first starting HIV treatment.
Trials of this combination have not suggested any increase in resistance compared with other combinations.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Private/For-Profit Healthcare Research Entity
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Director
- Medical Director
- Owner
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Infectious Diseases Physicians (US) | 885 |
| HIV Specialists (US) | 367 |
| Prescribers of Combivir : HIV Specialists (US) | 33 |
| Viread Prescribers for HIV (US) | 29 |
| Maraviroc Experts | 41 |
| Cubicin Prescribers (US) | 180 |
| Emtriva Prescribers for HIV (US) | 19 |
| Physicians who Treat HCV (US) | 111 |
GLG Live Meetings with this Study Group's Leading Experts (?)
February 20, 2008 | Boston
GLGi: Human Immunodeficiency Virus (HIV)February 23, 2007 | New York
GLGi: Emerging Therapies for HIV Grand RoundsFebruary 22, 2007 | Boston
GLGi: Emerging Therapies for HIVGLG Webcasts & Teleconferences
Leading Experts in Fuzeon Prescribers for HIV (US) have not participated in any GLG webcasts.